The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation

Neoplasia

Volumn 8, Issue 12, 2006, Pages 1037-1041

  Pajonk, Frank ^a   Grumann, Thorsten ^b   McBride, William H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

26S proteasome; Hypoxia; MG 132; Radiation response; Reoxygenation

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; PROTEASOME;

ARTICLE; CARCINOMA CELL; CELL HYPOXIA; CELL SURVIVAL; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REOXYGENATION; UTERINE CERVIX CARCINOMA;

EID: 33845588574     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06634     Document Type: Article

References (31)

1. Zolzer F and Streffer C (2002). Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int J Radiat Oncol Biol Phys 54, 910-920.
2. Kumar P (2000). Tumor hypoxia and anemia: impact on the efficacy of radiation therapy. Semin Hematol 37, 4-8.
3. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, and Vaupel P (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56, 4509-4515.
4. Denekamp J, Fowler JF, and Dische S (1977). The proportion of hypoxic cells in a human tumor. Int J Radiat Oncol Biol Phys 2, 1227-1228.
5. Rak JW, St Croix BD, and Kerbel RS (1995). Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6, 3-18.
6. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, and Giaccia AJ (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours [see comments]. Nature 379, 88-91.
7. Das DK, Engelman RM, and Kimura Y (1993). Molecular adaptation of cellular defences following preconditioning of the heart by repeated ischaemia. Cardiovasc Res 27, 578-584.
8. Pahl HL and Baeuerle PA (1994). Oxygen and the control of gene expression. Bioessays 16, 497-502.
9. Rupec RA and Baeuerle PA (1995). The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-kappa B. Eur J Biochem 234, 632-640.
10. Muller JM, Rupec RA, and Baeuerle PA (1997). Study of gene regulation by NF-kappa B and AP-1 in response to reactive oxygen intermediates. Methods 11, 301-312.
11. Adams GE, Hasan NM, and Joiner MC (1997). The Klaas Breur Lecture. Radiation, hypoxia and genetic stimulation: implications for future therapies. Radiother Oncol 44, 101-109.
12. Ciechanover A (1994). The ubiquitin-proteasome proteolytic pathway. Cell 79, 13-21.
13. Lee DH and Goldberg AL (1996). Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J Biol Chem 271, 27280-27284.
14. Tsubuki S, Saito Y, Tomioka M, Ito H, and Kawashima S (1996). Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem (Tokyo) 119, 572-576.
15. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, and Baldwin AS Jr (2001). Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61, 3535-3540.
16. Pajonk F, Pajonk K, and McBride WH (2000). Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 47, 1025-1032.
17. Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, and Cusack JC Jr (2001). Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50, 183-193.
18. Kane RC, Bross PF, Farrell AT, and Pazdur R (2003). Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8, 508-513.
19. Albright N (1987). Computer programs for the analysis of cellular survival data. Radiat Res 112, 331-340.
20. Zhang X, Kon T, Wang H, Li F, Huang Q, Rabbani ZN, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, and Li CY (2004). Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 64, 8139-8142.
21. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, and Wenger RH (2003). The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22, 3213-3220.
22. Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R, and Mercola D (1997). The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 272, 14041-14044.
23. Hahn GM and Little JB (1972). Plateau-phase cultures of mammalian cells: an in vitro model for human cancer. Curr Top Radiat Res Q 8, 39-43.
24. Deschavanne PJ, Fertil B, Chavaudra N, and Malaise EP (1990). The relationship between radiosensitivity and repair of potentially lethal damage in human tumor cell lines with implications for radioresponsiveness. Radiat Res 122, 29-37.
25. Weinmann M, Jendrossek V, Guner D, Goecke B, and Belka C (2004). Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB J 18, 1906-1908.
26. Fribley A, Zeng Q, and Wang CY (2004). Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress - reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24, 9695-9704.
27. Reinheckel T, Sitte N, Ullrich O, Kuckelkorn U, Davies KJ, and Grune T (1998). Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J 335, 637-642.
28. Reinheckel T, Ullrich O, Sitte N, and Grune T (2000). Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Arch Biochem Biophys 377, 65-68.
29. Pajonk F and McBride WH (2001). Ionizing radiation affects 26S proteasome function and associated molecular responses, even at low doses. Radiother Oncol 59, 203-212.
30. Krogan NJ, Lam MH, Fillingham J, Keogh MC, Gebbia M, Li J, Datta N, Cagney G, Buratowski S, Emili A, et al. (2004). Proteasome involvement in the repair of DNA double-strand breaks. Mol Cell 16, 1027-1034.
31. Wang QE, Wani MA, Chen J, Zhu Q, Wani G, El-Mahdy MA, and Wani AA (2005). Cellular ubiquitination and proteasomal functions positively modulate mammalian nucleotide excision repair. Mol Carcinog 42, 53-64.